The Evaluation of Lipoprotein Related Phospholipase A2 as a Target of Therapy in Occupational Lead Exposure

Year 2013, Volume: 13 Issue: 2, 66 - 70, 11.03.2014

Hınç Yılmaz Engin Tutkun Fatma Yılmaz Kübranur Karatoprak Halil Kara Bekir Keskinkılıç

Abstract

Purpose: Cardiovascular risk is known to be increased in lead-exposed workers, but there is no consensus about its mechanism. In this study, our aim is to evaluate the efficiency of using the lipoprotein and lipid parameters, which have been proposed as a risk factor and lipoprotein associated Phopholipase A2, which has been proposed as a potential atherosclerosis biomarker in recent years, as cardiac biomarkers in occupational lead exposure.Materials and Methods: Twenty-four workers, who have been exposed to lead occupationally and 24 healthy subjects were included in the study. Plasma atherogenic indexes were calculated with the analysis of the total HDL, LDL, non-HDL cholesterol, triglyceride. Groups were compared with the analysis of LP-PLA2.Findings: No statistically significant differences between the lipid parameters have been found among the two groups. LP-PLA2 levels were found to be higher in lead exposed workers, statistically. There was a meaningful correlation between LP-PLA2 and non-HDL cholesterol levels.Results: LP-PLA2 may be an important biomarker in the underlying mechanism of cardivascular diseases related to lead exposure. Supporting the study data with clinical cohort studies will provide the chance of using LP-PLA2 as a target of therapy in lead toxicity.

Keywords

Lead, occupational exposure, atherosclerosis, LP-PLA2, lipoprotein associated phospholipase A2

Lipoprotein İlişkili Fosfolipaz A2’nin Mesleki Kurşun Maruziyetinde Potansiyel Bir Kardiyak Belirteç Olarak Değerlendirilmesi

Abstract

Amaç: Kronikkurşunmaruziyetihastalarındakardiyovasküler hastalık riskinin arttığı bilinmekte, ancakmekanizması konusunda bir fikir birliği bulunmamaktadır.Yapılan çalışmada amaç, risk faktörü olarak önerilenlipoprotein ve lipid parametreleri ile son yıllarda potansiyelyeni bir ateroskleroz belirteci olarak sunulan Lipoproteinİlişkili Fosfolipaz A2 nin (LP-PLA2) mesleki kurşunmaruziyetinde kardiyak belirteç olarak değerlendirilmesidir.Materyal-Metod. Çalışmaya mesleki kurşun maruziyetiolan 24 işçi ve kurşun maruziyeti olabilecek bir işkolundaçalışmayan 24 sağlıklı birey dahil edilmiş; total, HDL, LDL,non-HDL kolesterol, trigliserit düzeyleri çalışılarak plazmaaterojenik indeksleri hesaplanmıştır. Ayrıca LP-PLA 2seviyeleri belirlenerek gruplar arasında karşılaştırılmıştır.

Bulgular: Çalışılan ve hesaplanan lipid parametreleri açısından gruplar arasında anlamlı farklılığa rastlanmamıştır. LP-PLA2 düzeyleri ise kurşun maruziyetiolan işçilerde kontrol grubuna oranla anlamlı şekilde yüksekbulunmuştur. LP-PLA2 düzeyleri ile non-HDL kolesteroldüzeyleri arasında anlamlı korelasyon saptanmıştır.

Sonuç: LP-PLA2 kurşun maruziyetinin kardiyovaskülerhastalığa yol açmasının mekanizmasının açıklanmasıadına önemli bir belirteç olabilir. Çalışma bulgularının klinikkohort çalışmalarla desteklenmesi, LP-PLA2 nin kurşunmaruziyetinde tedavi hedefi olarak değerlendirilmesine olanak sağlayacaktır.

Keywords

Kurşun, mesleki maruziyet, ateroskleroz, LP-PLA2, Lipoprotein ilişkili fosfolipaz A2

References

• Brannvall ML, Bindler R, Renberg I, Emteryd O, Bartnicki J, Billstrom K. The Medieval metal industry was the cradle of modern large scale atmospheric lead pollution in northern Europe. Environ. Sci. Technol. 1999; 33: 4391–5.
• Were FH, Kamau GN, Shiundu PM, Wafula GA, Moturi CM . Air and blood lead levels in lead acid battery recycling and manufactoring plants in Kenya. J Occup Environ Hyg 2012; 9: 340-4.
• Ercal N, Gurer-Orhan H, Aykin-Burns N. Toxic metals and oxidative stress. Part 1. Mechanisms involved in metalinduced oxidative damage. Curr Top Med Chem 2001; 1: 529–39.
• Gurer H, Ercal N. Can antioxidants be beneficial in the treatment of lead poisoning? Free Radic. Biol Med 2000; 29: 927–45.
• Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ. Lead exposure and cardiovascular disease--a systematic review. Environ Health Perspect 2007; 115: 472–82. Abadin H. Agency for Toxic Substances and Disease Registry. 2005. Toxicological Profile for Lead, Atlanta. U.S. Department of Health and Human Services, Public Health Service 2007: 43–59.
• Kaji T. Cell biology of heavy metal toxicity in vascular tissue. Yakugaku Zasshi 2004;124:113–20.
• Goch A, Goch JH. Lead-induced pathomechanisms of hypertension. Pol. Merkur. Lekarski. 2005; 18: 351–3. O’Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E. Lipoproteinassociated phospholipase a2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the prove it-timi 22 (pravastatin or atorvastatin evaluation and infection therapythrombolysis in myocardial infarction) trial. Circulation 2006; 113:1745-52.
• Sabatine MS, Morrow DA, O’Donoghue M, Jablonksi KA, Rice MM, Solomon S, Rosenberg Y, Domanski MJ, Hsia J. Prognostic Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease. Arterioscler Thromb Vasc 2007; 27: 2463-69.
• Tsimikas S, Willeit J, Knoflach M, Mayr M, Egger G, Notdurfter M, Witztum JL, Wiedermann CJ, Xu Q, Kiechl S. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J 2009; 30: 107-15.
• Li N, Li S, Yu C, Gu S. Plasma Lp-PLA2 in acute coronary syndrome: association with major adverse cardiac events in a community-based cohort. Postgrad Med 2010; 122: 200-20